Bija Ventures: Seeding the AI x Biology revolution.

We believe biology is entering its deployment phase—moving from artisanal discovery to an engineering discipline. We invest in TechBio: companies using AI to turn drug discovery from a game of chance into a predictable, scalable engine.

Why Bija?

Deep tech is a black box for most investors. We provide the diligence to understand it and the network to access it.

• Rigor: Our team combines big tech scale (Ish: ex-Waymo/Google) with preclinical rigor (Nelly & Colin: ex-BioAge, Earli). We don't just syndicate; we scrutinize. Every deal undergoes 40+ hours of institutional-grade diligence to separate true innovation from hype.

• Access: We target pre-seed to series A rounds in therapeutics and life science tools. Leveraging a network of 250+ VC firms, we secure allocation in oversubscribed rounds—giving you access to deals typically reserved for insiders.

The track record:

Our GPs have deployed capital into 53 companies representing $56B+ in value, including outliers like Perplexity and EigenLayer (Crypto Infra). We are now opening this institutional-grade access to you with minimums as low as $1k.

Join us to back the future of engineering medicine.

Questions? Reach out at team@bija.vc.